One of the most stubborn obstacles in brain cancer treatment is not the tumor itself — it is the blood-brain barrier, a molecular fortress that blocks roughly 98% of systemically administered drugs from reaching malignant tissue. For patients with recurrent glioblastoma, whose median survival after relapse historically sits between two and nine months, this biological wall has been a death sentence in slow motion. A new systematic review now consolidates the most rigorous clinical evidence to date on whether focused ultrasound can safely and effectively breach that barrier on demand.
Drawing from 12 clinical trials encompassing 841 patients and published between 2015 and 2024, the review evaluated four focused ultrasound platforms — SonoCloud-1, SonoCloud-9, ExAblate Neuro, and NaviFUS — each employing between one and ten sonication sessions of 2.5 to 22 minutes duration. Blood-brain barrier opening was confirmed in 68 to 100 percent of procedures, a remarkably consistent rate across devices and protocols. Critically, median overall survival in treated cohorts ranged from 9.95 to 18 months — figures that, while not yet from randomized controlled trials with matched controls, exceed the historical benchmark for this indication. The review adhered to PRISMA guidelines, utilized the ROBINS-I tool for bias assessment, and was prospectively registered in PROSPERO.
This synthesis arrives at a pivotal moment. The focused ultrasound field has matured from proof-of-concept animal models into early-phase human trials over the past decade, and aggregating 841 patients across standardized platforms begins to shift the evidence weight from anecdote toward emerging clinical signal. The survival figures are promising, but several limitations demand caution: most contributing studies are single-arm phase I or II trials without contemporaneous controls, patient selection likely favors those with better functional status, and the heterogeneity of concomitant chemotherapy regimens complicates attribution of benefit. Whether the observed survival gains derive from enhanced drug delivery, direct sonication effects, or patient selection remains mechanistically unresolved. Still, the safety profile across sessions — with barrier opening confirmed in the vast majority of procedures — suggests this is no longer experimental in concept but rather transitional toward phase III validation. For a disease with essentially no effective salvage options, that transition carries genuine clinical weight.